Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on June 26, 2020. The report details corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainer: $40,000 for Board service.
- Committee Retainers: $7,500 for the Compensation Committee and $5,000 for the Nominating and Corporate Governance Committee.
- Equity Grant: Option to purchase 38,000 shares at an exercise price of $17.03 per share.
Material Changes
The material change reported is the expansion of the Board of Directors and the appointment of Susan Shiff, Ph.D., M.B.A. as a new director. Dr. Shiff was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee. Her term expires at the 2021 Annual Meeting of Stockholders.
Outlook, Risks, and Management Commentary
Management highlighted Dr. Shiff's extensive background, including over 20 years in the pharmaceutical industry with leadership roles at Merck, Teva, Pfizer, Roche, and Johnson & Johnson. The filing notes that the Company expects to enter into its standard indemnification agreement with Dr. Shiff. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the correct registrant name is Cara Therapeutics, Inc. (Ticker: CARA).
- Confirm the vesting schedule of the 38,000 stock options (12 equal quarterly installments over three years).
- Review the standard director indemnification agreement referenced in the filing.
- Check for any subsequent filings regarding Dr. Shiff's committee assignments or additional compensation.